Back to Search Start Over

Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.

Authors :
Aayush A
Darji S
Dhawan D
Enstrom A
Broman MM
Idrees MT
Kaimakliotis H
Ratliff T
Knapp D
Thompson D
Source :
Oncotarget [Oncotarget] 2022 Sep 06; Vol. 13, pp. 1004-1016. Date of Electronic Publication: 2022 Sep 06 (Print Publication: 2022).
Publication Year :
2022

Abstract

Cystoscopic visualization of bladder cancer is an essential method for initial bladder cancer detection and diagnosis, transurethral resection, and monitoring for recurrence. We sought to develop a new intravesical imaging agent that is more specific and sensitive using a polypeptide based NIR (near-infrared) probe designed to detect cells bearing epidermal growth factor receptors (EGFR) that are overexpressed in 80% of urothelial carcinoma (UC) cases. The NIR imaging agent consisted of an elastin like polypeptide (ELP) fused with epidermal growth factor (EGF) and conjugated to Cy5.5 to give Cy5.5-N24-EGF as a NIR contrast agent. In addition to evaluation in human cells and tissues, the agent was tested in canine cell lines and tissue samples with naturally occurring invasive UC. Flow cytometry and confocal microscopy were used to test cell-associated fluorescence of the probe in T24 human UC cells, and in K9TCC-SH (high EGFR expression) and K9TCC-Original (low EGF expression) canine cell lines. The probe specifically engages these cells through EGFR within 15 min of incubation and reached saturation within a clinically relevant 1 h timeframe. Furthermore, ex vivo studies with resected canine and human bladder tissues showed minimal signal from normal adjacent tissue and significant NIR fluorescence labeling of tumor tissue, in good agreement with our in vitro findings. Differential expression of EGFR ex vivo was revealed by our probe and confirmed by anti-EGFR immunohistochemical staining. Taken together, our data suggests Cy5.5-ELP-EGF is a NIR probe with improved sensitivity and selectivity towards BC that shows excellent potential for clinical translation.<br />Competing Interests: CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.<br /> (Copyright: © 2022 Aayush et al.)

Details

Language :
English
ISSN :
1949-2553
Volume :
13
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
36082359
Full Text :
https://doi.org/10.18632/oncotarget.28271